{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=94", "query": { "condition": "Phase I", "page": 94 }, "page_size": 10 }, "pagination": { "page": 94, "page_size": 10, "total_count": 18752, "total_pages": 1876, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=95&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=93&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T19:43:51.842Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02607813", "title": "Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC", "Ovarian Cancer", "Melanoma", "Other Solid Tumors" ], "interventions": [ { "name": "LXH254", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2016-01-18", "completion_date": "2022-02-19", "has_results": false, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607813" }, { "nct_id": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "Hormone-Resistant Breast Cancer", "Non Small Cell Lung Cancer", "Mesothelioma" ], "interventions": [ { "name": "AG-01 Compound", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "A&G Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2022-02-14", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2022-11-28", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05627960" }, { "nct_id": "NCT05053659", "title": "Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Loncastuximab tesirine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paolo Caimi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-06-20", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05053659" }, { "nct_id": "NCT03321747", "title": "Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Stereotactic Ablative Body Radiation (SABR)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-10-20", "completion_date": "2020-07-09", "has_results": false, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 3, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03321747" }, { "nct_id": "NCT03415126", "title": "A Study of ASN007 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Malignancy", "Neoplasia", "Neoplasm", "Neoplasm Metastasis", "Colon Cancer", "Colonic Neoplasms", "Colon Cancer Liver Metastasis", "Metastatic Cancer", "Metastatic Melanoma", "Metastatic Colon Cancer", "Metastatic Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Pancreatic Cancer", "Pancreas Cancer", "Pancreas Adenocarcinoma", "Pancreas Neoplasm", "Metastatic Nonsmall Cell Lung Cancer", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ASN007: ascending doses", "type": "DRUG" }, { "name": "ASN007 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-01-19", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-09", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03415126" }, { "nct_id": "NCT00772915", "title": "Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2008-12-03", "completion_date": "2018-06-27", "has_results": true, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00772915" }, { "nct_id": "NCT00926640", "title": "A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma Neuroendocrine", "Small Cell Lung Carcinoma", "Malignant Epithelial Neoplasms" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 28, "start_date": "2009-07-01", "completion_date": "2018-04-20", "has_results": false, "last_update_posted_date": "2018-10-19", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00926640" }, { "nct_id": "NCT01535040", "title": "Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Lung Cancer", "Prostate Cancer", "Tobacco Use Disorder" ], "interventions": [ { "name": "memantine hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2012-08-01", "completion_date": "2014-02-01", "has_results": true, "last_update_posted_date": "2021-09-28", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535040" }, { "nct_id": "NCT01364350", "title": "TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetes Mellitus Type 2 in Obese" ], "interventions": [ { "name": "standard of care in general clinical practice", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "12 Years to 24 Years" }, "enrollment_count": 550, "start_date": "2011-03", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2021-08-04", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 16, "location_summary": "Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01364350" }, { "nct_id": "NCT04580485", "title": "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Bladder Cancer", "Non Small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple Negative Breast Cancer", "Castration Resistant Prostate Cancer", "Colorectal Cancer", "Gastric/ Gastroesophageal Junction", "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Squamous Carcinoma of the Anal Canal" ], "interventions": [ { "name": "INCB106385", "type": "DRUG" }, { "name": "INCMGA00012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-02-03", "completion_date": "2024-01-22", "has_results": false, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-11-12T19:43:51.842Z", "location_count": 8, "location_summary": "West Hollywood, California • Baltimore, Maryland • Boston, Massachusetts + 5 more", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580485" } ] }